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In Brief
Jin et al. show that cdk4 activation
triggers non-alcoholic fatty liver disease
(NAFLD) development. They find that an
increased level of cdk4 protein in mice
and humans leads to C/EBPa-p300
complex formation and hepatic steatosis.
Disruption of this pathway or inhibition of
cdk4 prevents NAFLD development and
reverses steatosis.
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The development of non-alcoholic fatty liver dis-
ease (NAFLD) is a multiple step process. Here, we
show that activation of cdk4 triggers the develop-
ment of NAFLD. We found that cdk4 protein levels
are elevated in mouse models of NAFLD and in
patients with fatty livers. This increase leads to
C/EBPa phosphorylation on Ser193 and formation
of C/EBPa-p300 complexes, resulting in hepatic
steatosis, fibrosis, and hepatocellular carcinoma
(HCC). The disruption of this pathway in cdk4-re-
sistant C/EBPa-S193A mice dramatically reduces
development of high-fat diet (HFD)-mediated
NAFLD. In addition, inhibition of cdk4 by flavopiridol
or PD-0332991 significantly reduces development
of hepatic steatosis, the first step of NAFLD. Thus,
this study reveals that activation of cdk4 triggers
NAFLD and that inhibitors of cdk4 may be used
for the prevention/treatment of NAFLD.INTRODUCTION
NAFLDgenerally developsunder conditions of high-fat diet (HFD)
andagingas thediseaseprogressesover several stages. Thefirst
stage is thedevelopment of hepatic steatosis,which is character-
ized by an accumulation of triglycerides (TGs) in the cytoplasm of
hepatocytes. Hepatic steatosis can further progress to non-alco-
holic steatohepatitis (NASH) and ultimately to cirrhosis and hepa-
tocellular carcinoma (HCC) if not treated or prevented (Cohen
et al., 2011; Hebbard and George, 2011). With advanced age,
patients develop hepatic steatosis and have an increased risk
in developing liver cancer (Schmucker, 2005; Timchenko,
2011). Accumulation of fat in the liver (hepatic steatosis) might
be a result of multiple alterations of fat metabolism, including
enhanced fat uptake, increased lipogenesis, and decreased
secretion of very-low-density lipoproteins (Cohen et al., 2011).
C/EBPa and C/EBPb are two members of the C/EBP family.
Members of this protein family contain a basic region and a744 Cell Reports 16, 744–756, July 19, 2016 ª 2016 The Author(s).
This is an open access article under the CC BY-NC-ND license (http://leucine zipper region (Johnson, 2005), and they dimerize and
control multiple functions in different tissues. C/EBPa is
required for liver differentiation, where it acts as a strong inhib-
itor of liver proliferation (Timchenko, 2009; Wang et al., 2006).
The biological activities of C/EBPa are mainly controlled by
post-translational modifications. Among several important
modification sites is Ser193, a key amino acid of C/EBPa
through which multiple functions of C/EBPa are regulated,
including its role in the biology of the liver (Wang and Tim-
chenko, 2005; Jin et al., 2010; Wang et al., 2010). It has been
shown that cyclin D3-cyclin-dependent kinase 4 (cdk4) phos-
phorylates C/EBPa on Ser193, causing C/EBPa to associate
with the chromatin remodeling protein p300. C/EBPa-p300
complex formation results in alterations of chromatin structure
(Jin et al., 2010) that, in turn, lead to C/EBPa-dependent growth
arrest (Wang et al., 2010, Jin et al., 2010). Our recent paper (Jin
et al., 2013) showed that phosphorylation of C/EBPa at Ser193
regulates steatosis.
An important regulator of C/EBPa activity, cdk4 is activated
by D-type cyclins (D1 and D3) and mediates progression of
the cell cycle through G1 phase by phosphorylation of retino-
blastoma protein (Rb) and subsequent release of Rb-depen-
dent repression of S-phase genes (Baker and Reddy, 2012).
Cdk4 and cdk6 are highly homologous and share many proper-
ties. Therefore, the majority of the information about cdk6 also
applies to cdk4. Crystal structures of the p16-cdk6 complexes
revealed that p16 interacts with amino acid residues located in
the active sites of cdk4 and cdk6 and diminishes kinase activ-
ities of cdk4 and cdk6 (Gil and Peters, 2006; Endicott et al.,
1999). A systematic screen for cdk4/cdk6 substrates in
HEK293 cells identified a broad number of substrates (Anders
et al., 2011). Since cdk4 is involved in the development of can-
cer, cdk4 inhibition is under intensive investigation for cancer
therapy. The initial development of cdk4/6 inhibitors led to
the discovery of the first generation of inhibitors, such as flavo-
piridol (FPD) and roscovitine (Dickson and Schwartz, 2009).
Further research for more specific and non-toxic inhibitors
has identified a small compound, PD-0332991, which seems
to be the best inhibitor of cdk4/6. It has been shown that
PD-0332991 causes G1 growth arrest by blocking phosphory-
lation of Rb (Rivadeneira et al., 2010).creativecommons.org/licenses/by-nc-nd/4.0/).
In this study, we found that the triggering event in the develop-
ment of HFD-mediated NAFLD is the elevation of cdk4 and sub-
sequent promotion of C/EBPa-p300 complexes. Disruption of
this pathway by genetic mutation of C/EBPa and by inhibition
of cdk4 significantly inhibits the development of NAFLD.
RESULTS
Cdk4 Is Activated by HFD and Phosphorylates C/EBPa at
Ser193, Leading to an Increase of C/EBPa-p300
Complexes
We have shown previously that the elevation of C/EBPa-p300
complexes is involved in the development of hepatic steatosis.
Since cdk4 phosphorylates Ser193 and increases the formation
of C/EBPa-p300 complexes (Jin et al., 2013), we examined if
cdk4 is activated in wild-type (WT) mice during the development
of NAFLD under HFD conditions.WTmicewere treatedwith HFD
for 3 and 12 weeks, and livers were harvested and examined for
the expression of proteins of the cyclin D3-cdk4-C/EBP-p300
pathway. Representative results are shown in Figure 1A. We
found that both cyclin D3 and cdk4 are elevated at 3 and
12weeks of HFD and that this elevation leads to increased phos-
phorylation of C/EBPa at Ser193. Co-immunoprecipitation (coIP)
studies showed that amounts of C/EBPa-p300 complexes are
increased in livers of mice at 3 and 12 weeks of HFD (Figure 1B).
Note that levels of C/EBPa, C/EBPb, and p300 also were
increased at 3 and 12 weeks of HFD. However, these proteins
form a tripartite complex only if C/EBPa is phosphorylated at
Ser193 (Jin et al., 2013, 2015). Based on these data, we hypoth-
esized that cdk4 is a key protein that increases C/EBPa-p300
complexes under conditions of HFD in mice, leading to NAFLD.
Cdk4-C/EBPa-p300 Pathway Is Activated in Patients
with NAFLD
Given activation of cdk4-C/EBPa-p300 in HFD-mediated
NAFLD in mice, we next asked if this pathway is activated in
livers of patients with NAFLD. Western blotting with nuclear ex-
tracts isolated from control livers and from livers of NAFLD
patients showed that cdk4 is significantly increased in NAFLD
patients (Figure 1C). Calculation of cdk4 as a ratio to b-actin
revealed that cdk4 is 6- to 8-fold elevated in livers of patients
with NAFLD. We next examined cdk4 expression in two control
livers and in four livers from patients with NAFLD using immu-
nostaining approaches. This assay showed that cdk4 is
increased in all examined samples from patients with fatty liver
disease (Figure 1D).
We have shown previously that human C/EBPa is phosphory-
lated at Ser190 in the livers of these patients (Jin et al., 2013).
Therefore, we next examined if this phosphorylation might result
in the formation of C/EBPa-p300 complexes using the coIP
approach. We found that amounts of these complexes are
increased in livers of NAFLD patients (Figure 1E). Because the
C/EBPa-p300 complexes activate promoters of enzymes of TG
synthesis, we examined expression of key enzymes GPAT and
DGAT2, which catalyze the first and last steps of TG synthesis.
Figure 1F shows that expression of both enzymes is increased
in livers of patients with NAFLD. Thus, these data demonstrated
that the cdk4-C/EBPa-p300 pathway is activated in patients withNAFLD and correlates with the elevation of enzymes of TG syn-
thesis. From the results obtained in mice and data collected in
humans, we hypothesized that cdk4 might be a key triggering
event in the development of hepatic steatosis and further stages
of NAFLD (Figure 1G).
HFD-Mediated Hepatic Steatosis Is Inhibited in
Cdk4-Resistant S193A Mice
To examine if cdk4-dependent phosphorylation of C/EBPa at
Ser193 is involved in the development of NAFLD, we
utilized two knockin mouse models: constitutively active
C/EBPa-S193D mice (Wang et al., 2010; Jin et al., 2010) and
recently generated cdk4-resistant C/EBPa-S193A mice (Jin
et al., 2015). Due to the fact that C/EBPa cannot be phosphory-
lated at Ser193 by cdk4 in S193Amice, we first examined if these
mice expressing cdk4-independent C/EBPa might be resistant
to the development of hepatic steatosis in a short time frame
of HFD protocol. We treated S193A mice with HFD for 3 and
12 weeks. An identical treatment was performed with S193D
mice and with WT mice as the controls.
Figure 2A shows H&E and oil red O staining of livers under
normal diet (ND) and 3 and 12 weeks of HFD. In agreement
with previous observations, WT mice developed steatosis at 3
and 12 weeks while S193D mice had much stronger steatosis
at the same time points. In S193A mice, however, both H&E
and oil red O staining showed no steatosis at 3 weeks and a
much weaker steatosis at 12 weeks. These data indicate that
knockin mice expressing the cdk4-resistant C/EBPa-S193A
mutant are also resistant for development of hepatic steatosis
within 12 weeks of HFD. Since steatosis is inhibited in S193A
mice and because these mice have reduced basal levels of
glucose (Jin et al., 2013), we asked if these animals might have
changes in insulin sensitivity. Therefore, we performed an insulin
tolerance test (ITT); however, no differences were detected in in-
sulin sensitivity between WT and S193A mice. Insulin-mediated
glucose lowering was identical in both groups (Figure 2B).
Note that, while the ITT showed the reduction of the glucose
as a percentage to the levels observed before insulin injection,
the levels of glucose were lower in S193A mice during the entire
duration of the test (Figure S1).
Cdk4-Resistant S193A Mice Do Not Accumulate
C/EBPa-p300 Complexes
We next determined a molecular basis for the resistance of
S193A mice to develop steatosis. We first examined if cdk4
and cyclin D3 are properly activated in S193A mice. Similar
to WT mice, both these proteins were increased in livers of
S193A mice at 3 and 12 weeks of HFD (Figures 2C and 2E).
Examination of C/EBPa and p300 proteins also showed that
they are elevated in WT and S193A mice at 3 and 12 weeks,
with a slightly lower elevation in S193A mice. In agreement
with observations shown in Figures 1A and 1B, coIP studies re-
vealed that C/EBPa-p300 complexes are elevated in WT mice;
however, these complexes were not detectable in livers of
S193A mice after HFD treatments (Figure 2C). These data
clearly demonstrated that the mutation of S193 to Ala blocked
the formation of C/EBPa-p300 complexes in the animals under
HFD protocol.Cell Reports 16, 744–756, July 19, 2016 745
A D G
B
C E F
Figure 1. Cdk4 Is Activated in Animal Models of NAFLD and in Patients with NAFLD
(A) Cyclin D3/cdk4-C/EBP-p300 pathway is activated inmouse livers after HFD treatment. Western blotting shows that cyclinD3, cdk4, ph-C/EBPa, and p300 are
increased in livers after HFD treatment.
(B) C/EBPa-p300 complexes are elevated during development of hepatic steatosis in mice. C/EBPa was immunoprecipitated from nuclear extracts and
immunoprecipitates were examined bywestern blotting with antibodies to p300. Upper image shows input of the proteins (IgG, signals of immunoglobulins on the
immunoprecipitate membranes). Images in (A) and (B) represent typical pictures of three independent experiments with three mice at each time point. Exami-
nation of additional mice is shown in Figure 2C.
(C) Protein levels of cdk4 are increased in livers of patients with fatty liver disease. Western blotting was performed with total protein extracts isolated from the
livers. The membrane was re-probed with antibodies to b-actin. Bar graph shows a summary of three independent experiments.
(D) Immunostaining of normal livers and livers from four patients with fatty liver diseases using antibodies to cdk4. The slides were stained with DAPI. The right
panel shows enlarged pictures of merged images.
(E) Protein levels of p300 and C/EBPa-p300 complexes are increased in livers of patients with fatty liver diseases. Upper image: western blotting was performed
with total protein extracts isolated from the livers. The membrane was re-probed with antibodies to b-actin. Bar graphs show calculations of p300 and
C/EBPa-p300 complexes as ratios to b-actin.
(F) Amounts of DGAT2 and GPAT are increased in livers of patients with fatty liver diseases. Western blotting was performed with total protein extracts isolated
from the livers. The membranes were re-probed with antibodies to b-actin. Bar graph shows levels of GPAT and DGAT2 as ratios to b-actin.
(G) A model shows hypothetical mechanisms for the development of NAFLD (see Results).The Lack of C/EBPa-p300 Complexes Resulted in the
Failure of S193A Mice to Activate Enzymes of TG
Synthesis and Enzymes of Glucose Synthesis
Our previous studies have shown that C/EBPa-p300 complex is
a positive regulator of enzymes of TG synthesis, GPAT and
DGAT1/2 (Jin et al., 2013), and enzymes of glucose synthesis,
PEPCK and G6-phase (Jin et al., 2015). The reduction of G6-
phase in S193A mice also recently has been reported (Fleet
et al., 2015). Since these proteins are key regulators of hepatic746 Cell Reports 16, 744–756, July 19, 2016steatosis, we asked if their levels might be changed in livers of
S193A mice under conditions of HFD protocol. We found that
GPAT, DGAT1, DGAT2, PEPCK, and G6-phase are elevated in
livers of WT mice at 3 and 12 weeks of HFD; however, no eleva-
tion of these proteins was detected in livers of S193A mice (Fig-
ure 2D). SinceGPAT, DGAT1, andDGAT2 are key enzymes of TG
synthesis, the failure of activation of these proteins by p300-
C/EBPa complexes in S193A mice seems to be the main mech-
anism of the inhibition of hepatic steatosis.
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Figure 2. Cdk4-Resistant C/EBPa-S193A Mice Do Not Develop Hepatic Steatosis under Conditions of an HFD Protocol
(A) S193A mice do not develop hepatic steatosis, while S193D mice are developing hepatic steatosis much faster than WT mice after 3 and 12 weeks of HFD
conditions. Typical pictures of H&E and oil red O staining of WT, S193D, and S193A livers (five mice of each genotype) are shown at 3 and 12 weeks after the
initiation of an HFD. Scale bar, 40 mm.
(B) Insulin-dependent lowering of glucose is not affected in S193Amice. ITT was performedwithWT and S193Amice as shown in the Supplemental Experimental
Procedures.
(C) Cyclin D3-cdk4 pathway is identically elevated in WT and S193A mice, but C/EBPa-p300 complexes are not formed in livers of S193A mice. Western blotting
was performed with antibodies to cdk4, cyclin D3, C/EBPa, and p300. Bottom image: C/EBPa was immunoprecipitated from nuclear extracts and p300 was
examined in these immunoprecipitates. IgG, signals of immunoglobulins detected on the membrane.
(D) Expression of enzymes of TG synthesis, glucose synthesis, and lipidmetabolism. Cytoplasmic extracts fromWT and S193Amice were probedwith antibodies
shown on the left. Membranes were re-probed with antibodies to b-actin.
(E) Levels of proteins in (C) and (D) were calculated as ratios to b-actin. The bar graph shows a summary of three repeats with threemice per time point. Additional
calculations are shown in Figure S2.To further investigate if other lipogenic pathways are altered in
S193A mice, we examined the expression of FASN, ACC, and
SCD by western blotting, and we found that these lipogenic
pathways are activated in livers of WT mice at 3 and 12 weeks
but livers of S193Amice do not increase expression of these pro-
teins (Figure 2D). Thus, these data revealed that cdk4-resistant
S193A mice do not develop hepatic steatosis under HFD
protocol and that this correlates with a failure to form the
C/EBPa-p300 complexes and to activate genes that are involved
in the development of hepatic steatosis.
Development of HFD-Mediated Fibrosis Is Inhibited in
S193A Mice
It has been shown that long-term treatments of mice with HFD
leads to further development of NAFLD, including progressionto fibrosis, cirrhosis, and HCC. Therefore, we next examined if
disruption of the cdk4-C/EBPa pathway in S193A mice might
affect the development of fibrosis under an HFD protocol. Previ-
ous studies showed that fibrosis is very well developed in mouse
livers at 6–7 months after the initiation of an HFD protocol (Hill-
Baskin et al., 2009). Therefore, we fed WT, S193D, and S193A
mice with an HFD for 7 months and examined fibrosis using
several approaches.H&Eandoil redOstainingshowed that,while
WTandS193Dmice have significant accumulation of fat droplets,
the development of hepatic steatosis is weaker in S193A mice
(Figure 3A). Examination of livers under a higher magnification
showed that there are detectable differences in the liver structure
(Figure3B).Wenext examineddevelopment of fibrosis by staining
livers with Sirius Red, and we found that the development of
fibrosis is significantly inhibited in S193A mice (Figure 3A).Cell Reports 16, 744–756, July 19, 2016 747
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Figure 3. Development of NAFLD and Fibrosis Is Inhibited in S193A Mice after 7 and 12 Months of HFD Treatments
(A) Typical pictures of H&E, oil redO, and Sirius Red staining ofWT, S193D, and S193A livers under HFD conditions. Upper image showsH&E staining of the livers,
middle image shows oil red O staining, and bottom image shows Sirius Red staining. Scale bar, 40 mm.
(B) Sections of H&E staining under high magnification are shown.
(C) Typical pictures of H&E and oil red O staining of WT, S193D, and S193A livers under 12 months of HFD conditions. Upper image shows H&E staining of the
livers and bottom image shows oil red O and a-SMA staining. The figure shows typical pictures obtained with livers of five mice of each genotype. Scale
bar, 40 mm.C/EBPa-S193AMiceHaveReducedHepatic Steatosis at
12 Months of HFD
We next studied the development of NAFLD in S193A mice after
very long treatments with HFD. For this goal, five mice of each
genotype were treated with HFD for 48 weeks (12 months). All
animals survived these long treatments, but WT and S193D
mice were fatty and, as expected, developed liver disease.
H&E staining showed that S193Dmice developed severemacro-
vesicular steatosis and that liver architecture was significantly
destroyed with significant loss of hepatocytes (Figure 3C). Livers
of WT mice also developed these disorders but to a lesser de-
gree. Contrary to these two mouse lines, S193A livers had
much less steatosis and relatively abundant hepatocytes (Fig-
ure 3C). Oil red O staining confirmed that development of steato-
sis is inhibited in S193A livers after 12 months of HFD protocol.
Examination by a-SMA staining showed that the development
of fibrosis is also inhibited in S193A mice (Figure 3C).
NAFLD Is Reduced but Liver Proliferation Is Increased in
S193A Mice after 12 Months of HFD
The 12-month duration of HFD protocol usually initiates develop-
ment of liver cancer. One of the characteristics of liver cancer is748 Cell Reports 16, 744–756, July 19, 2016increased liver proliferation. To examine the degree of liver pro-
liferation in our animal models, we performed a set of studies us-
ing several approaches. First, we calculated number of mitotic
figures and found that all three mouse models have increased
mitosis after 12 months of HFD, but the levels of mitosis are
different. Despite higher steatosis, the mitosis in S193D mice
was lower than in WT mice. On the contrary, cdk4-resistant
S193Amice had higher levels of proliferation but much less stea-
tosis (Figures 4A and 4B). Second, we performed ki67 staining
and found that proliferation of S193A hepatocytes is significantly
higher than one of WT livers, while S193D mice have a reduced
number of ki67-positive hepatocytes (Figures 4A and 4B). These
results are consistent with growth-inhibitory/tumor-suppressive
activities of C/EBPa mutants S193D and S193A (Wang et al.,
2010; Jin et al., 2015), and they suggest that the S193D mutant
inhibits liver proliferation under HFD protocol while S193A
does not.
We next examined expression of cdk4 and phosphorylation
status of C/EBPa in our animal models after 7 and 12 months
of HFD treatments. In these studies, we incorporated protein
extracts of 3-month-HFD-treated mice. Figure 4D shows that
cdk4 was activated in all three mouse lines and that C/EBPa
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Figure 4. 12-Month Treatments with an HFD Lead to Increased Liver Proliferation and Initiation of Cancer-Specific FXR-Gank Pathway
(A) Left panel: H&E staining shows mitotic figures. Middle and right panels: ki67 staining of livers after 12 months of HFD is shown.
(B) Bar graph shows numbers of mitotic figures in WT, S193D, and S193A mice per 1,000 hepatocytes.
(C) Bar graph shows percentages of ki67-positive hepatocytes. Three animals of each genotype were used for calculations of mitotic figures and BrdU uptake.
(D) The cdk4-cyclin D3 pathway in WT, S193D, and S193A mice at 7 and 12 months after the initiation of an HFD protocol. Nuclear extracts were isolated from
livers and used for western blotting with Abs shown on the left.
(E) Amounts of cdk4 are increased in nuclei of hepatocytes after HFD treatment. Liver sections were stained with antibodies to cdk4 and with DAPI. Enlarged
images of merged pictures are shown on the bottom.
(F) Cancer-specific FXR-Gank pathway is activated in WT, S193D, and S193A mice after 7 and 12 months of an HFD. Expression of FXR and Gankyrin was
determined in livers after 7 and 12 months of an HFD. Three animals for each genotype were used in these experiments.
(G) A diagram summarizes the examination of mechanisms of NAFLD in genetically modified animal models.was phosphorylated at Ser193 in WT mice, but not in S193A
mice. Interestingly, ph-S193-specific antibodies also recognized
the S193D mutant, which was reduced at 12 months of HFD in
livers of S193D mice. Examination of cyclin A as an indicator of
proliferation revealed that cyclin A is increased in all mouse lines
at 7 and 12months of HFD. In these studies, we found that cyclin
A also is activated inWTmice after 3months of HFD protocol. To
examine intracellular localization of cdk4 after 12months of HFD,
we immunostained livers of WT mice with antibodies to cdk4.
This assay confirmed that cdk4 is significantly increased in livers
of HFD-treated mice at 7 and 12 months and that the major frac-
tion of cdk4 is located in the nucleus (Figure 4E).
Our previous observations were that the development of liver
cancer under conditions of DEN-mediated carcinogenesis is
facilitated by a downregulation of farnesoid X receptor FXR
and upregulation of an oncogene Gankyrin, Gank (Jiang et al.,
2013). To examine if this pathway of liver cancer is initiated after7 and 12 months of HFD, we used qRT-PCR approach with
mRNA isolated from WT, S193D, and S193A mice. In WT mice,
we detected a dramatic reduction of FXR at 7 months and a
3-fold reduction at 12 months. In agreement with the role of
FXR as a repressor of Gank, the levels of Gank were 2- to
4-fold elevated inWTmice at 7 and 12months of HFD. Examina-
tion of S193D and S193A mice surprisingly showed that FXR is
reduced in both these lines without treatments; but, it was
slightly elevated in S193D and reduced in S193Amice compared
to non-treated animals (Figure 4F). However, comparisons to the
levels of FXR in WT non-treated mice showed that levels of FXR
are reduced in all three mouse lines after 7 and 12 months of an
HFD protocol. We also found that levels of Gank are elevated in
both S193D and S193A mice at 12 months after the initiation of
an HFD protocol (Figure 4F). Taken together, these data demon-
strated that 12-month HFD treatments of all three mouse lines
lead to the severe steatosis in WT and S193D mice and thatCell Reports 16, 744–756, July 19, 2016 749
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Figure 5. Inhibition of Cdk2/Cdk4 Activities by FPD Prevents Development of Hepatic Steatosis and Inhibits Liver Proliferation
(A) Oil red O staining of livers of mice treated with normal diet (ND), with HFD + vehicle, and with HFD + FPD is shown.
(B) Western blotting of protein extracts with antibodies to enzymes of TG synthesis, DGAT1 and DGAT2, and examination of cdk4-C/EBPa pathway in livers of
mice treated with HFD and HFD + FPD. Western blotting was performed with Ab shown on the right. LAP and LIP are isoforms of C/EBPb. Bottom image shows
coIP studies in which p300 was immunoprecipitated and C/EBPa was examined in these immunoprecipitates.
(C) Expression of cell-cycle proteins was examined by western blotting.
(D) H&E and ki67 staining of livers of mice treated with ND, with HFD, and with HFD + FPD. 403 shows ki67 staining under 403 magnification.
(E) Percentages of mitotic figures are shown.
(F) Percentages of ki67-positive hepatocytes. Four animals of each group were used for calculations of mitotic figures and ki67 staining.
(G) Liver proliferation was examined in mice after 3 and 12 weeks of an HFD using ki67 staining. Left images show typical pictures of ki67 staining. Bar graph
shows percentages of ki67-positive hepatocytes.
(H) A diagram summarizes examination of effects of FPD on HFD-mediated steatosis and liver proliferation.steatosis is inhibited in livers of S193A mice. We also found that
liver proliferation is significantly increased and cancer-specific
FXR-Gank pathway is activated in all three lines; however, liver
proliferation was not strongly activated in S193D mice due to
growth-inhibitory activity of this mutant.
Inhibition of Cdk4 by FPD Prevents Development of the
First Stage of NAFLD, Hepatic Steatosis
Figure 4G summarizes the examination of HFD-mediated NAFLD
in our animal models. Given a strong inhibition of NAFLD in
cdk4-resistant C/EBPa-S193A mice, we asked if the inhibition
of cdk4 by pharmacological intervention might reduce the devel-
opment of hepatic steatosis (Figure 4G) in the mice under HFD750 Cell Reports 16, 744–756, July 19, 2016protocol. In the first set of experiments, we used FPD as the in-
hibitor of cdk4. Note that FPD also inhibits cdk2 (Nagaria et al.,
2013; Luke et al., 2012). Control WT mice were treated with
HFD, while experimental mice were treated with HFD plus FPD
for 5 weeks. Examination of livers by oil red O staining showed
that control mice develop hepatic steatosis; however, FPD-
treated mice did not show detectable steatosis (Figure 5A). Ex-
amination of enzymes of TG syntheses DGAT1 and DGAT2
showed significant increases in HFD control mice, but no eleva-
tion was observed in livers of mice treated with FPD (Figure 5B).
To examine if FPD inhibits the activity of cdk4, we performed
western blotting with antibodies to a target of cdk4, ph-780-Rb
protein. These data revealed that HFD-mediated activation of
cdk4 leads to significant phosphorylation of Rb, FPD completely
inhibits cdk4 activity, and phosphorylated forms of Rb are not
detectable in livers of mice treated with FPD (Figure 5B).
We next examined cdk4-C/EBPa-p300 pathway in livers of
control and FPD-treated mice. Although our original hypothesis
was that the inhibition of cdk4 by FPD might block phosphoryla-
tion of C/EBPa and subsequent formation of complexes with
p300, we were surprised to find that the inhibition of cdk2/
cdk4 by FPD has a much broader and much stronger effect
on the expression of several components that are involved
in the formation of C/EBPa-p300 complexes. Particularly, we
observed that FPD inhibits HFD-mediated elevation of cyclin
D3, C/EBPa, C/EBPb, and p300, while these proteins are
elevated in control HFD-treated mice (Figure 5B). In agreement
with the reduction of C/EBPa and p300 proteins, we could not
detect C/EBPa-p300 complexes in FPD-treated mice (Fig-
ure 5B). Given the unexpected results showing the reduction of
protein levels of C/EBP proteins, which inhibit liver proliferation,
we performed a careful examination of liver proliferation in WT
mice. Examination of cell-cycle proteins showed activation of
cyclin E, cdc2, and cdk2 in control mice treated by HFD; how-
ever, FPD completely blocked the activation of all these proteins
(Figure 5C).
We also studied the number of mitotic figures and number of
ki67-positive hepatocytes. In agreement with the effects of
FPD on cell-cycle proteins, we observed that HFD significantly
increases mitosis and number of ki67-positive hepatocytes
and that FPD blocks this activation (Figures 5D–5F). Given these
unexpected results showing the activation of liver proliferation by
a very short treatment (5 weeks) with an HFD, we examined if
proliferation of the liver was initiated in WT mice at early time
points using animals shown in Figure 2. These animals were
treated with an HFD for 3 and 12 weeks. Ki67 staining revealed
that 3 weeks of HFD treatments are sufficient to initiate liver pro-
liferation (Figure 5G). Figure 5H summarizes our examination of
the effects of FPD on HFD-mediated steatosis. We found that
HFD induces both liver proliferation, by activating cdk2/cdk4,
and NAFLD, through elevation of p300-C/EBPa complexes.
The inhibition of cdk2/cdk4 by FPD blocks the development of
hepatic steatosis and liver proliferation.
Inhibition of Cdk4 by a More Specific Inhibitor,
PD-0332991, Inhibits Development of HFD-Dependent
Hepatic Steatosis, but Does Not Block Liver
Proliferation
Our data for increase of liver proliferation are in agreement with a
previous report showing that an HFD initiates liver proliferation,
which correlates with inflammatory changes (Vansaun et al.,
2013). Our data demonstrated that this elevation of proliferation
occurs at very early time points (3 weeks after the initiation of an
HFD protocol, Figure 5G), suggesting that this increase contrib-
utes to the further development of steatosis. To address
this issue, we utilized a more specific inhibitor of cdk4,
PD-0332991 (Flaherty et al., 2012; Leonard et al., 2012), in a
similar setting of HFD-mediated steatosis. Note that we used a
dose of PD-0332991 that was much lower than that described
in the literature. Oil red O staining and western blotting with an-
tibodies to DGAT1 and DGAT2 revealed that PD-0332991 (givenwith chow, 150 mg/kg chow) prevents the development of HFD-
mediated hepatic steatosis (Figures 6A and 6B). To examine if
this block of hepatic steatosis is mediated by the inhibition of
cdk4 activity, we looked at the phosphorylation status of its tar-
gets Rb-Ser780 and C/EBPa-S193-ph. Western blotting with
specific antibodies showed that both substrates are phosphory-
lated after treatments with HFD and that inhibition of cdk4 blocks
or significantly reduces this phosphorylation (Figure 6B). CoIP
studies revealed that the inhibition of cdk4 and reduction of
S193-ph isoform of C/EBPa dramatically reduces C/EBPa-p300
complexes (Figure 6C).
We next examined if the inhibition of cdk4 by PD-0332991
blocks liver proliferation using three approaches. Examination
of cell-cycle proteins, cyclin D1, cyclin D3, cdk2, and cdc2,
and counting the number of ki67-positive hepatocytes showed
that treatment with PD-0332991 does not prevent the increase
of liver proliferation initiated by HFD (Figures 6B, 6D, and 6F).
To get additional support for this result, we examined DNA repli-
cation by measuring BrdU uptake, and we found that
PD-0332991 treatment does not inhibit liver proliferation under
the conditions of our experiments (Figures 6E and 6G). Figure 6H
shows a summary of these studies. We found that HFD-medi-
ated hepatic steatosis and HFD/cdk2-4-mediated increase of
liver proliferation are parallel events and that HFD-mediated liver
proliferation does not seem to contribute to the development of
hepatic steatosis. These data and the lack of C/EBPa-p300
complexes strongly suggest that the cdk4-C/EBPa-p300
signaling is the main cause of hepatic steatosis.
Inhibition of Cdk4 by PD-0332991 in Mice with Existing
Hepatic Steatosis Reverses NAFLD
Althoughourdata clearly show that inhibition of cdk4prevents the
development of hepatic steatosis, thenext important question is if
the inhibition of cdk4might reverseexisting steatosis. This is quite
important because the patients with NAFLD need an approach to
cure NAFLD. To test if the treatment with PD-0332991 reverses
hepatic steatosis, we applied a strategy shown in Figure 7A.
Four groups of mice were used for the 5- and 10-week duration
of the treatments. The first group was fed an HFD for 5 weeks.
The second group was fed an ND, while the third group was fed
anHFD for the entire 10-week duration of the protocol. The fourth
experimental groupwas fedanHFD for the first 5weeks, and then
an HFD plus PD-0332991 were given for the next 5 weeks. Ani-
mals were sacrificed 5 or 10 weeks after initiation of the protocol,
and hepatic steatosis was examined by oil red O staining. Fig-
ure 7B shows that the 5-week-HFD group developed significant
steatosis and that the 10-week-HFD group of mice further
developed severe steatosis. However, inhibition of cdk4 by
PD-0332991 dramatically reduced steatosis in the fourth group
compared to both 5- and 10-week-HFD groups. Thus, these
data demonstrated that inhibition of cdk4 reverses hepatic stea-
tosis, even with continued treatments with an HFD.
We next examined the cdk4-C/EBPa pathway in mice treated
for 10 weeks with an HFD and an HFD plus PD-0332991. West-
ern blotting showed that, although protein levels of cdk4 are not
reduced by PD-0332991, the activity of cdk4 is dramatically in-
hibited and Rb is not phosphorylated in mice treated with the in-
hibitor (Figure 7C). Consistent with oil red O results, amounts ofCell Reports 16, 744–756, July 19, 2016 751
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Figure 6. Inhibition of Cdk4 by Specific Inhibitor PD-0332991 Prevents Development of Steatosis, but Does Not Block Liver Proliferation
(A) Oil red O staining of mice treated with an ND, an HFD, and an HFD + PD-0332991 is shown.
(B) Western blotting with antibodies shown on the right. LAP and LIP are isoforms of C/EBPb protein. CRM, cross-reactive molecule.
(C) Examination of C/EBPa-p300 complexes by coIP approach is shown.
(D and E) Examination of liver proliferation by (D) ki67 staining and (E) BrdU uptake. Typical pictures are shown.
(F and G) Bar graphs show percentages of (F) ki67-positive and (G) BrdU-positive hepatocytes.
(H) A diagram summarizing examination of effects of PD-0332991 on HFD-mediated steatosis and liver proliferation. Data in this figure show analyses of four to
five mice of each group.DGAT1 and DGAT2 proteins were reduced in mice treated with
the inhibitor. We next examined C/EBPa-p300 complexes using
the coIP approach. Figure 7D shows that C/EBPa-p300 com-
plexes were significantly reduced or were not detectable in
mice with inhibited cdk4 activity. These results clearly de-
monstrate that the PD-0332991-mediated reversal of hepatic
steatosis is associated with the inhibition of cdk4 and with the
subsequent reduction of C/EBPa-p300 complexes. Because
an HFD also initiates liver proliferation, we asked if reversion of
the steatosis by PD-0332991 involves the inhibition of liver pro-
liferation. Three approaches were used: examination of cell-cy-
cle proteins cdc2 and cdk2, BrdU uptake, and staining with
antibodies to ki67. Figure 7C shows that levels of cdk2 and
cdc2 were increased by HFD and that the inhibition of cdk4 in
mice with existing steatosis did not reduce levels of these pro-
teins. Figure 7E shows typical pictures of BrdU and ki67 staining.
Calculations of BrdU-positive and ki67-positive hepatocytes752 Cell Reports 16, 744–756, July 19, 2016showed that, at the low doses used in our experiments,
PD-0332991 does not inhibit liver proliferation in the reversal
experiments (Figures 7F and 7G). Taken together, these data re-
vealed that PD-0332991-mediated inhibition of cdk4 reverses
hepatic steatosis through the disruption of C/EBPa-p300 com-
plexes, but does not affect the HFD-mediated proliferation of
the liver (Figure 7H).
DISCUSSION
Recent methodological progress has determined a number of
global changes that are associated with NAFLD (Hebbard and
George, 2011). Despite this progress, very little is known about
key events causing the development of NAFLD. NAFLD in hu-
mans is usually associated with age and inappropriate diet,
which first lead to the development of hepatic steatosis and
further progress into fibrosis, NASH, and HCC. One of the best
Figure 7. Inhibition of Cdk4 in Mice with Existing Hepatic Steatosis Dramatically Reduces Steatosis
(A) A diagram shows the strategy of experiments.
(B) Oil red O staining of livers. Typical pictures of four mice per group are shown.
(C) Inhibition of cdk4 activity by PD-0332991 and expression of DGAT1 and DGAT2 proteins. Western blotting was performed with Abs shown on the right.
(D) Inhibition of cdk4 activity by PD-0332991 reduces amounts of C/EBPa-p300 complexes. Input: western blotting with Abs to C/EBPa and p300 shows
expression and input of these proteins. P300-IP: examination of p300 immunoprecipitates by western blotting with Abs to C/EBPa is shown. 42- and 30-kD
C/EBPa isoforms are shown by arrows.
(E) Typical pictures show ki67 staining and BrdU uptake.
(F and G) Percentages of (F) ki67-positive and (G) BrdU-positive hepatocytes were calculated. Bar graphs represent summary of analyses of five mice per group.
(H) A diagram shows the results of reversion of HFD-mediated steatosis by PD-0332991-mediated inhibition of cdk4.and biologically relevant animal models of NAFLD is the HFD
treatment of mice. This treatment mimics the main steps of
development of NAFLD in humans: hepatic steatosis, fibrosis,
NASH, cirrhosis, and HCC. Transcription factors of the C/EBP
family, C/EBPa and C/EBPb, are key factors that are involved
in the development of NAFLD.
We previously have generated two C/EBPa knockin mouse
models in which Ser193 is mutated to Aspartate (S193D) and
to Alanine (S193A). We found that S193D mice develop hepatic
steatosis much faster than WT mice due to an elevation of
C/EBPa/b-p300 complexes, which activate five enzymes of TG
synthesis (Jin et al., 2013). This work suggested that there might
be a kinase that is activated during the development of NAFLD
and triggers NAFLD. In this paper, we have identified cdk4 as
such kinase, which is activated in mouse models of NAFLDand in patients with fatty liver disease. Our paper presents exper-
imental evidence showing that the inhibition of cdk4 by specific
inhibitors and/or blocking of the phosphorylation of its down-
stream target C/EBPa by genetic mutation of Ser193 to Ala
dramatically inhibits the development of NAFLD in animal
models. These data clearly demonstrate that the inhibitors of
cdk4 can be considered for the treatment of NAFLD in patients.
It is interesting that cdk4 inhibitor PD-0332991 is used in clinical
trials for the treatment of patients with liver cancer (Flaherty et al.,
2012; Leonard et al., 2012), suggesting that it might be easily
used for the treatment of NAFLD patients.
Although the HFD-mediated initiation of liver proliferation has
been reported previously (Vansaun et al., 2013), the contribution
of the liver proliferation to NAFLD had not been examined. We
found that a very short treatment of mice with an HFD (3 weeks)Cell Reports 16, 744–756, July 19, 2016 753
is sufficient to initiate liver proliferation. This finding raised the
question if liver proliferation might contribute to the development
of steatosis and further steps of NAFLD. Figures 5H, 6H, and 7H
summarize our findings and present our hypotheses based on
experiments with two inhibitors of cdk2/cdk4 and with geneti-
cally modified S193D and S193A mice. We found that increased
liver proliferation is not involved in the development of hepatic
steatosis. In fact, hepatic steatosis was much stronger in
S193D mice, in which the proliferation was significantly lower
than in WT and S193A mice (Figures 4A–4C). This opposite cor-
relation suggests that the increased proliferation in WT mice
might be a mechanism by which liver tries to block the develop-
ment of NAFLD. It is also important to emphasize that our
research identified a relationship between C/EBPa and FXR.
Our results show that FXR is a downstream target of C/EBPa
and that FXR is reduced in livers of animal models, S193A and
S193D mice (Figure 4). Since many reports revealed that FXR
is involved in the development of NAFLD (Carr and Reid, 2015;
Xu et al., 2014), this finding suggests that the cdk4-C/EBPa
pathway also might promote NAFLD through regulation of FXR.
The critical finding of our work is the identification of a key
event in the development of NAFLD, which is the elevation/acti-
vation of cdk4. This finding and further work with inhibitors of
cdk4 provide strong support for the consideration of cdk4 inhi-
bition as a promising possible treatment, which prevents liver
from the development of steatosis and might reduce existing
steatosis. It is important to note that liver injury is one of
the main causes of NAFLD. Our studies of cdk4-resistant
C/EBPa-S193A mice showed significant inhibition of liver injury
and the inhibition of steatosis at 7 and 12 months of an HFD
protocol. On the contrary, knockin mice expressing constitu-
tively active C/EBPa-S193D mutant have much more severe
liver injury than WT or S193A mice, and they develop severe
steatosis especially at 12 months after the initiation of an
HFD. In experiments with prevention and the reversal of steato-
sis, we examined if inhibitors of cdk2/cdk4 might prevent/
reverse liver injury. However, within the duration of these exper-
iments (10 weeks), we did not detect alterations of ALT/AST in
WT mice. We also performed TUNEL staining and immunoblot-
ting of livers for activated caspase 3. Under the conditions of
our experiments, these approaches did not detect liver injury
within the 10-week duration of the HFD protocol. On the other
hand, our experiments with Sirius Red detected a very minor
staining of livers of WT mice treated with an HFD for 10 weeks,
while this staining was not detected in animals treated with
HFD plus PD-0332991 (Figure S3). Since the development of
HFD-mediated fibrosis/liver injury requires long treatments
with an HFD (up to 7 months), it would be important to perform
long-term studies with HFD treatments and test if cdk4 inhibi-
tors might block the development of HFD-mediated fibrosis in
this setting.
At this stage of investigation, it is important to note that we
previously have examined ALT/AST in S193D and S193A
mice (Jin et al., 2015; Wang et al., 2010), and we found that
ALT and AST are elevated in S193D mice while they are
reduced in S193A mice. It is likely that the less injury in
S193A mice in the beginning of an HFD protocol might be
involved in protection from NAFLD. It is interesting to mention754 Cell Reports 16, 744–756, July 19, 2016that, while we have used relatively low doses of PD-0332991,
we detected very strong prevention and reversion of steatosis
within the time frame of 10 weeks of HFD treatments. It is
also important to mention that, in reversal experiments, we
kept feeding the HFD and PD-0332991 simultaneously for
5 weeks, and, despite HFD, the inhibitor of cdk4 dramatically
reduced hepatic steatosis. This study gives great hope that
cdk4-based therapy might be a worthy approach to treat pa-
tients with NAFLD, at least at early stages of the disease.
Further studies with animals are required to test if cdk4 inhibi-
tors might reverse late steps of NAFLD, such as fibrosis and
NASH. Considering treatments of NAFLD patients with inhibi-
tors of cdk4, it is important to keep in mind that, although
PD-0332991 is a more specific inhibitor of cdk4, there is a
risk for the development of liver cancer because it does not
inhibit liver proliferation. From this point of view, inhibition of
cdk4 by FPD might have a better outcome. In summary, our
work elucidated the key event in the HFD-mediated NAFLD,
and it provided the strong support for consideration of cdk4 in-
hibitors as a possible tool to treat NAFLD.
EXPERIMENTAL PROCEDURES
Animals
HFD Protocol
Experiments with animals were approved by the Institutional Animal Care and
Use Committee (IACUC) at Baylor College of Medicine (protocol AN-1439) and
by the IACUC at Cincinnati Children’s Hospital (protocol IACUC2014-0042).
In this study, we used 2- to 4-month-old WT, C/EBPa-S193D, and
C/EBPa-S193A mice. Generation and characterization of C/EBPa-S193D
and C/EBPa-S193A mice were described in our previous papers (Wang
et al., 2010; Jin et al., 2010, 2013). Livers were harvested and kept
at 80C. For HFD experiments, mice and their age-matched littermate con-
trols were fed either a standard laboratory chow diet or an HFD (D12331,
Research Diets) for 3 or 12 weeks for a short-term study or for 20–48 weeks
for long-term studies.
Inhibition of Cdk4 by FPD and PD-0332991
To inhibit activity of cdk4, we fed animals with inhibitors in chow diet (custom
made by BioServ) ad libitum for 7 days prior to the initiation of an HFD protocol.
After the 1-week pre-treatment, mice were given an HFD and were kept on the
0.025% FPD or PD-0332991 (in chow, 150 mg/kg chow) for 4 additional
weeks. At the end of experiments, mice were sacrificed, and livers were exam-
ined for the development of hepatic steatosis and for the expression of genes
as described below. Five mice per group of the protocol were used. In the
reversal studies, we used four groups of mice (five mice/group, males). The
protocol for reversal studies is summarized in Figure 7A.
Liver Histology and Immunohistochemistry
The livers were fixed overnight in buffered 10% formaldehyde, embedded in
paraffin, and sectioned at a thickness of 5 mm. The sections were then stained
with H&E using a standard protocol or with different antibodies against cdk4
(C-22, Santa Cruz Biotechnology). For oil red O staining of lipid droplets in
frozen liver sections, the liver cryosections of 7 mmwere stained with commer-
cially available kits (IW-3008, IHC World). Sirius Red staining was performed
using a Direct Red 80 (Sirius Red, Sigma-Aldrich) kit.
Antibodies and Reagents
Antibodies to C/EBPb (C-19), C/EBPa (14AA), DGAT1 (H-255), DGAT2 (H-70),
GPAT, PEPCK, G6-phase, p300 (N-15 or C-20), cdk4 (C-22), and cyclin D3
(C-16) were from Santa Cruz Biotechnology. Antibodies to FASN, SCD1, and
ACC were from Cell Signaling Technology. Antibodies to Ser193-ph C/EBPa
were purchased from Thermo Scientific (PA5-37342). Monoclonal anti-b-actin
antibody was from Sigma. CoIP studies were performed using TrueBlot re-
agents as previously described (Jin et al., 2013, 2015).
Protein Isolation and Western Blotting
Cytoplasmic and nuclear extracts were isolated from livers of mice as
described previously (Wang et al., 2010; Jin et al., 2015). Inhibitors of phospha-
tases were included in all buffers used for the isolation of proteins or protein-
protein complexes. Proteins (50–100 mg) were loaded on gradient (4%–20%)
polyacrylamide gels, transferred ontomembranes, and probedwith antibodies
against proteins of interest. To verify protein loading, each filter was re-probed
with Abs to b-actin.
Real-Time qRT-PCR
Total RNA was isolated from mouse livers using RNEasy Plus mini kit
(QIAGEN). The cDNA was synthesized with 2 mg total RNA using a High-Ca-
pacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific). The cDNA
was diluted five times with diethylpyrocarbonate (DEPC)-treated water and
subsequently used for RT-PCR assays with the TaqMan Gene Expression sys-
tem (Applied Biosystems). Gene expression analysis was performed using the
TaqMan Universal PCR Master Mix (Applied Biosystems) in a total volume of
10 ml containing 5 ml Master Mix, 1.5 ml water, 3 ml cDNA template, and
0.5 ml of the gene-specific TaqMan Assay probe mixture. The cycling profile
was 50C for 2 min, 95C for 10 min, followed by 40 cycles of 95C for 15 s
and 60C for 1 min, as recommended by the manufacturer. TaqMan probe
mixture for FXR (Mm00484523_m1), Gankyrin (Mm00450376_m1), and b-actin
(Mm02619580-g1) was purchased from Applied Biosystems. All results were
normalized to b-actin. Amplification and quantification were done with the
Applied Biosystems StepOne Plus RT-PCR System.
Statistical Analysis
All values are presented as means ± SD. Statistical analyses were performed
using the Student’s t test. Statistical significance was assumed when *p < 0.05
and **p < 0.01.
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